CERE INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Cerevel Therapeutics Holdings, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

Core Viewpoint - A class action lawsuit has been filed against Cerevel Therapeutics Holdings, Inc., Bain Capital Investors, LLC, and Pfizer, alleging violations of federal securities laws related to the merger with AbbVie Inc. [1][2] Group 1: Class Definition - The lawsuit seeks damages for individuals and entities that sold or disposed of Cerevel's common stock from October 11, 2023, to August 1, 2024, and were harmed by the defendants' violations of Section 10(b) of the Securities Exchange Act of 1934 [2] - It also includes those who held shares as of January 8, 2024, and were entitled to vote on the merger, as well as those who sold shares contemporaneously with Bain's purchase on or about October 16, 2023, alleging harm from Bain's violations of Section 20A of the Exchange Act [2] Group 2: Case Details - The Complaint alleges that Cerevel's Offering documents omitted material facts regarding AbbVie's interest in acquiring Cerevel at a price significantly higher than the $22.81 per share Offering price, which artificially deflated Cerevel's stock price until the merger announcement [3] - It is claimed that Bain acquired shares at an artificially depressed price while possessing material nonpublic information about AbbVie's interest, leading to a windfall of over$120 million when AbbVie agreed to acquire Cerevel for $45 per share [3] Group 3: Proxy Statement Allegations - The lawsuit also seeks damages for investors who held shares as of the January 8, 2024, Record Date, alleging that Cerevel's January 18, 2024, Proxy statement contained false and misleading statements regarding AbbVie's interest in the company [4] Group 4: Next Steps - Investors who suffered losses in Cerevel have until June 3, 2025, to request to be appointed as lead plaintiff in the class action lawsuit [5]